Topical effect of cicer arientinumr extract on some clinical signs of knee osteoarthritis: a randomized and double blind clinical trial

Topical effect of cicer arientinumr extract on some clinical signs of knee osteoarthritis: a randomized and double blind clinical trial

a double blind clinical trial

The present study is done in the second half of 1396 on patients with osteoarthritis referring to Rheumatology clinic of Rafsanjan. The amount of pain, morning stiffness, range of motion and function of patients in all three interventional groups at the beginning and the end of the study, will be evaluated with the linear-visual pain scale and the WOMAC scale. cicer arientinum is prepared by a pharmaceutical specialist. data will analyzed by spss v19

1. inclusion criteria: Age 50 - 70 years, Diagnosis of knee osteoarthritis according to the American College of Rheumatology criteria, which approved by Rheumatologist., The presence of moderate knee pain within 24 hours based on the linear-visual pain scale (VAS) between 4 to 7 cm 2. exclusion criteria: Patients with inflammatory diseases (such as lupus, rheumatoid arthritis, history of brucellosis, etc.), cancer or severe illness, Symptoms or history of liver or kidney failure, Corton consumption in the last 4 weeks, Corton injection over the past 6 months, Fever, Consumption of herbal medicine continuously, Sensitivity to cicer arientinum , Unwillingness to continue participating in the study, Failure to observe the study protocol, See any complications caused by cicer arientinumr , Use of food and pharmaceutical supplements, daily painkiller consumption, Very advanced disease.

Patients are divided into three groups A, B, and C . In group A, the pyroxycam gel, in group B cicer arientinum extraction and in group C paraffin for placebo will used topically.

Linear-visual pain scale and WOMAC scale

for double blind study creating, before the study begins, the drugs will be enclosed by someone ( not researcher ) in the same packages and encoded in A, B, and C. Rheumatologist prescribed as either A or B or C which drug delivery is done by another person. Assessment of clinical symptoms is done by a resident who is not aware of the type of drug consumption.